Mississippi boards jointly bar providers from research-grade peptides

Mississippi's Board of Medical Licensure, Board of Nursing and Board of Pharmacy issued a joint statement barring the people they license from compounding, administering, dispensing, recommending or prescribing peptides that are not FDA-approved or that are sold as "research-grade." The statement also bars licensees from delegating those acts to someone else ^[1].

The full text of the Mississippi statement was not available to us, so details such as its effective date, the specific peptides named, and the penalties for violating it are not yet known from the sources reviewed here ^[1].

The federal backdrop

States cannot allow less than federal law permits when it comes to compounding, but they can add requirements on top of it ^[2]. The federal baseline sits in Sections 503A and 503B of the Food, Drug and Cosmetic Act ^[2].

Two federal tracks are currently moving in opposite directions. On peptides generally, the FDA in 2023 put a group of popular peptides into "Category 2" of an interim scheme for bulk substances, effectively blocking their compounding on safety grounds. In April 2026 the agency removed twelve of those peptides from Category 2 and scheduled Pharmacy Compounding Advisory Committee meetings to consider some of them for the 503A Bulks List. Removal from Category 2 is not the same as permission to compound — those peptides now sit in a gray zone, neither flagged as unsafe nor cleared ^[2].

On GLP-1s specifically, the rules have tightened. Semaglutide and tirzepatide were never on the 503A or 503B bulks lists; large-scale compounding was allowed only through the drug shortage pathway, and that closed once the FDA declared both shortages resolved. The agency has since issued compliance policy guidance on what counts as compounding "essentially a copy" of an approved drug, proposed excluding these molecules from the 503B Bulks List, and sent waves of warning letters to compounders and telehealth marketers ^[2].

How Mississippi fits with other states

A state-by-state survey published August 6, 2026 by law firm Sheppard Mullin grouped states into five buckets and noted that nearly every state taking a position had addressed GLP-1 compounding specifically, not the broader peptide category ^[2]. Mississippi was not among the states discussed in that survey ^[2].

California is described as the only state with a substantive rule stricter than federal law, effective October 1, 2025, requiring pharmacists to document a clinically significant, patient-specific difference and requiring certificates of analysis to name the ingredient manufacturer ^[2]. Ohio's July 2025 guidance expressly prohibits the investigational peptides retatrutide and cagrilintide, and its pharmacy board reports summarily suspending more than thirty clinics and medical spas since the start of 2025 ^[2]. Washington's pharmacy commission issued a semaglutide statement and imposed a stop-service order on a sterile compounder ^[2]. Alabama reached physician-office compounding through a medical board declaratory ruling, not just the pharmacy board — a structure similar in spirit to Mississippi's multi-board approach ^[2][1].

The survey also flags that ingredients labeled "research use only" should never be used in compounded medicines, and that investigational GLP-1s without an approved reference product should be avoided ^[2].

Why it matters for patients

Mississippi's statement reaches three professions at once — physicians, nurses and pharmacists — so it applies to med spas, weight-loss clinics and telehealth prescribers operating in the state, not only to pharmacies ^[1]. Patients receiving peptide injections that are not FDA-approved products may find a provider stops offering them, changes the product, or refers them elsewhere.

The practical difference between an FDA-approved GLP-1 (Ozempic, Wegovy, Rybelsus for semaglutide; Mounjaro and Zepbound for tirzepatide) and a compounded or "research-grade" peptide is who verified the ingredient, its purity and its labeling. Compounded products are not FDA-approved, and marketing that implies otherwise has drawn both FDA and state consumer-protection enforcement ^[2].

Cost and access questions are not addressed in the Mississippi statement as summarized, and it is not known whether existing patients are given any transition period ^[1].

What happens next

The FDA's compounding advisory committee is scheduled to consider whether several of the twelve peptides removed from Category 2 in April 2026 belong on the 503A Bulks List ^[2]. Because most states default to the federal standard, that outcome will shape state policy without further state action — though states with their own codified rules or aggressive boards may stay stricter ^[2]. Separately, Lilly and Novo Nordisk have filed trademark, patent and false advertising suits across dozens of jurisdictions, with at least one compounder countersuing on antitrust grounds ^[2].